Freeze Lift Allows Cel-Sci And Ergomed Motor On With Multikine
Executive Summary
The biggest Phase III trial in head and neck cancer is resuming after the FDA lifted a freeze on trials evaluating CEL-SCI's lead asset Multikine in the indication, giving a boost to its commercial prospects.